144 related articles for article (PubMed ID: 37846578)
1. BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review.
Zhang M; Li Y; Zhang Z; Zhang X; Wang W; Song X; Zhang D
Curr Drug Targets; 2023; 24(14):1079-1092. PubMed ID: 37846578
[TBL] [Abstract][Full Text] [Related]
2. [Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].
Gao RL; Zeng CW; Li YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1365-1368. PubMed ID: 34362532
[TBL] [Abstract][Full Text] [Related]
3. [Advances of structure and mechanisms of bromodomain-containing protein 4 and its related research in tumors].
Huang Q; Ding Y; Tan Y; Mo W; Li T; Huang Y; Hao W
Sheng Wu Gong Cheng Xue Bao; 2023 Jan; 39(1):132-148. PubMed ID: 36738206
[TBL] [Abstract][Full Text] [Related]
4. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review).
Yongprayoon V; Wattanakul N; Khomate W; Apithanangsiri N; Kasitipradit T; Nantajit D; Tavassoli M
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38606512
[TBL] [Abstract][Full Text] [Related]
5. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
6. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
7. BRD4 in physiology and pathology: ''BET'' on its partners.
Liang Y; Tian J; Wu T
Bioessays; 2021 Dec; 43(12):e2100180. PubMed ID: 34697817
[TBL] [Abstract][Full Text] [Related]
8. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
9. KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
Qiang Y; Fan J; Xie C; Yan L; Song X; Zhang N; Lin Y; Xiong J; Zhang W; Liu Y; Wei L; Li Y; Chen S; Liang K; Li F
Cancer Res; 2024 Apr; 84(8):1252-1269. PubMed ID: 38285760
[TBL] [Abstract][Full Text] [Related]
10. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of BRD4 in Gastric Cancer and its Clinical Significance as a Novel Therapeutic Target.
Zhang M; Huang H; Wei M; Sun M; Deng G; Hu S; Wang H; Gong Y
Curr Cancer Drug Targets; 2024; 24(2):167-177. PubMed ID: 37282642
[TBL] [Abstract][Full Text] [Related]
12. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
13. IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors.
Wu SY; Lai HT; Sanjib Banerjee N; Ma Z; Santana JF; Wei S; Liu X; Zhang M; Zhan J; Chen H; Posner B; Chen Y; Price DH; Chow LT; Zhou J; Chiang CM
Mol Cell; 2024 Jan; 84(2):202-220.e15. PubMed ID: 38103559
[TBL] [Abstract][Full Text] [Related]
14. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
15. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
16. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer.
Rodriguez RM; Huidobro C; Urdinguio RG; Mangas C; Soldevilla B; Domínguez G; Bonilla F; Fernandez AF; Fraga MF
J Mol Med (Berl); 2012 May; 90(5):587-95. PubMed ID: 22120039
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
[TBL] [Abstract][Full Text] [Related]
18. BRD4 and Cancer: going beyond transcriptional regulation.
Donati B; Lorenzini E; Ciarrocchi A
Mol Cancer; 2018 Nov; 17(1):164. PubMed ID: 30466442
[TBL] [Abstract][Full Text] [Related]
19. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
20. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
